4-[3-(1-adamantyl)-4-allyloxybenzoyloxy] benzoic acid | 135077-49-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: 4-[3-(1-adamantyl)-4-allyloxybenzoyloxy] benzoic acid
• 英文别名: 4-[3-(1-Adamantyl)-4-allyloxybenzoyloxy]benzoic acid；4-[3-(1-adamantyl)-4-prop-2-enoxybenzoyl]oxybenzoic acid
• CAS: 135077-49-5
• 化学式: C₂₇H₂₈O₅
• 分子量: 432.516
• InChiKey: IVNNVIZNBJPKMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-[3-(1-adamantyl)-4-hydroxybenzoyloxy] benzoic acid 、 3-溴丙烯 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 以68%的产率得到4-[3-(1-adamantyl)-4-allyloxybenzoyloxy] benzoic acid
  参考文献：
  名称：

  Bi-aromatic esters, a process for their preparation and their use in

  摘要：

  双芳香酯的化学式为##STR1##其中R.sub.1代表H，OH，--CH.sub.3，--CH.sub.2 OH，--CH(OH)CH.sub.3，--COOR.sub.9，##STR2##或SO.sub.2 R.sub.10；R.sub.9代表H，C.sub.1 -C.sub.6烷基或单或多羟基烷基；R.sub.10代表OH，C.sub.1 -C.sub.6烷基或##STR3##r'和r"代表H，C.sub.1 -C.sub.6烷基，芳基，芳基烷基，单或多羟基烷基，或r'和r"一起形成杂环；R.sub.2代表H，C.sub.1 -C.sub.6烷基，OR.sub.9，F或--CF.sub.3；R.sub.3，R.sub.4和R.sub.5代表H，F，OH，--CH.sub.3，--OCH.sub.3，--CF.sub.3，--COOH或--CH.sub.2 OH；R.sub.6和R.sub.8代表H，α-取代的C.sub.3 -C.sub.15烷基，α，α'-二取代的C.sub.4 -C.sub.12烷基，C.sub.3 -C.sub.12环烷基，C.sub.5 -C.sub.12单环或多环环烷基，其连接碳为三取代，--SR.sub.11，--SO.sub.2 R.sub.11或--SOR.sub.11；R.sub.11代表C.sub.1 -C.sub.6烷基或环烷基；R.sub.6和R.sub.8不能同时代表H；R.sub.7代表H，C.sub.1 -C.sub.6烷基，烯烃基，烯烃氧基，OR.sub.12或SR.sub.13；R.sub.12代表H，C.sub.1 -C.sub.6烷基或烯烃基；R.sub.3代表H，C.sub.1 -C.sub.6烷基或芳基；但有一个例外，当R.sub.1代表##STR4##且R.sub.2代表H时：(i)要么R.sub.3和R.sub.4不是H或--CH.sub.3，(ii)或者R.sub.7不是OR.sub.12且R.sub.6或R.sub.8是具有超过7个碳原子的环烷基，(iii)或者R.sub.7是OR.sub.12但R.sub.6和R.sub.8不是H，(iv)或者R.sub.7是OR.sub.12但R.sub.5不是H。这些双芳香酯在人类和兽医药物以及化妆品配方中被使用。

  公开号：

  US05200550A1

文献信息

• Esters bi-aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique
  申请人：CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA)

  公开号：EP0409728B1

  公开（公告）日：1995-03-01
• Composition pharmaceutique ou cosmétique contenant en association un rétinoîde et un stérol
  申请人：CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA

  公开号：EP0465343B1

  公开（公告）日：1994-06-15
• CaM Kinase II Inhibitor Improves Retinoic Acid Therapy and Inhibits the Proliferation of Myeloid Leukemia Cells
  申请人：Collins Steven J.

  公开号：US20080255244A1

  公开（公告）日：2008-10-16

  A method of treating a cancer (e.g., myeloid leukemia) in a subject in need thereof, is carried out by administering the subject a CaM kinase II (CaMK II) inhibitor. In some embodiments, the CaMK II inhibitor is administered concurrently with a retinoid. In some embodiments, the CaMK II inhibitor is CaMK II gamma inhibitor. Compositions and formulations useful for carrying out such methods are also described.
• USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN
  申请人：Fabius Biotechnology

  公开号：US20210338558A1

  公开（公告）日：2021-11-04

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.
• US5200550A
  申请人：——

  公开号：US5200550A

  公开（公告）日：1993-04-06